Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Safety of Roflumilast Cream in Chronic Plaque Psoriasis
NCT03764475Phase 2Completed
- Sponsor
- Arcutis Biotherapeutics
- Start
- Dec 2018
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of roflumilast in plaque psoriasis, sponsored by Arcutis Biotherapeutics. Primary endpoints: Treatment-emergent Adverse Events at 52 weeks and Serious Adverse Events at 52 weeks. Started Dec 2018; status: completed.
02
Drugs
roflumilast
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT03764475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03764475.